SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-24-010512 to CytoDyn Inc. (CYDY)

CytoDyn Inc.
Date: Sept. 17, 2024 · CIK: 0001175680 · Accession: 0000000000-24-010512

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-282000

Date
September 17, 2024
Author
Mitchell Cohen
Form
UPLOAD
Company
CytoDyn Inc.

Letter

September 17, 2024 Mitchell Cohen Interim Chief Financial Officer CytoDyn Inc. 1111 Main Street, Suite 660 Vancouver, Washington 98660 Re:CytoDyn Inc. Registration Statement on Form S-1 Filed September 9, 2024 File No. 333-282000 Dear Mitchell Cohen: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Mary Ann Frantz

Show Raw Text
September 17, 2024
Mitchell Cohen
Interim Chief Financial Officer
CytoDyn Inc.
1111 Main Street, Suite 660
Vancouver, Washington 98660
Re:CytoDyn Inc.
Registration Statement on Form S-1
Filed September 9, 2024
File No. 333-282000
Dear Mitchell Cohen:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Mary Ann Frantz